Market Overview

Piper Jaffray Reiterates Overweight and PT of $20 on DexCom


Piper Jaffray reiterated its Overweight rating on DexCom (NASDAQ: DXCM). At the same time, Piper Jaffray left its price target on the company's stock unchanged at $20. On Friday, DexCom lost 0.54% of its value to end the week at $14.60.

Posted-In: dexcom Piper JaffrayReiteration Analyst Ratings


Related Articles (DXCM)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

JP Morgan Lowers PT On Scotts Miracle-Gro To $56

Immunodiagnostic Systems sees profits surge and secures FDA clearance for new automated assays